REV‐ERB agonism suppresses osteoclastogenesis and prevents ovariectomy‐induced bone loss partially via FABP4 upregulation

What is it about?

Excessive bone resorption due to increased osteoclast formation and activity is common in diseases such as osteoporosis, rheumatoid arthritis, periodontitis, multiple myeloma, metabolic bone diseases and Paget's bone disease. And suppressing osteoclast differentiation is a promising treatment for osteoclast-related disorders. In this study, we found that REV-ERBs function as suppressors of osteoclast differentiation. Furthermore, the dual REV-ERBs agonist SR9009 dramatically inhibited osteoclast differentiation while showing no apparent cytotoxicity. The results from the ovariectomy mouse models showed that SR9009 ameliorated ovariectomy-induced bone loss. These results suggested that the pharmacological activation of REV-ERBs may be a promising method for treating osteoclast-related disorders.

Featured Image